

RESMED INC  
Form 10-Q  
October 31, 2014  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2014**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 001-15317**

**ResMed Inc.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: RESMED INC - Form 10-Q

**Delaware**

(State or other jurisdiction of incorporation or organization)

**98-0152841**

(I.R.S. Employer Identification No.)

**9001 Spectrum Center Blvd.**

**San Diego, CA 92123**

**United States of America**

(Address of principal executive offices)

**(858) 836-5000**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐ (Do not check if a smaller reporting company)

Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At October 21, 2014, there were 139,444,592 shares of Common Stock (\$0.004 par value) outstanding. This number excludes 37,629,964 shares held by the registrant as treasury shares.

**Table of Contents**

**RESMED INC. AND SUBSIDIARIES**

**INDEX**

|                |   |           |
|----------------|---|-----------|
| <b>Part I</b>  | <b><u>Financial Information</u></b>   | <b>3</b>  |
| Item 1         | <u>Financial Statements</u>   | 3         |
|                | <u>Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2014 and June 30, 2014</u>                                 | 3         |
|                | <u>Condensed Consolidated Statements of Income (Unaudited) for the Three Months Ended September 30, 2014 and 2013</u>               | 4         |
|                | <u>Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the Three Months Ended September 30, 2014 and 2013</u> | 5         |
|                | <u>Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended September 30, 2014 and 2013</u>           | 6         |
|                | <u>Notes to the Condensed Consolidated Financial Statements (Unaudited)</u>   | 7         |
| Item 2         | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>  | 16        |
| Item 3         | <u>Quantitative and Qualitative Disclosures About Market Risk</u>   | 22        |
| Item 4         | <u>Controls and Procedures</u>  | 24        |
| <b>Part II</b> | <b><u>Other Information</u></b>   | <b>25</b> |
| Item 1         | <u>Legal Proceedings</u>  | 25        |
| Item 1A        | <u>Risk Factors</u>   | 25        |
| Item 2         | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>  | 25        |
| Item 3         | <u>Defaults Upon Senior Securities</u>  | 25        |
| Item 4         | <u>Mine Safety Disclosures</u>  | 25        |
| Item 5         | <u>Other Information</u>  | 25        |
| Item 6         | <u>Exhibits</u>   | 26        |
|                | <u>Signatures</u>   | 27        |

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**Item 1. Financial Statements****RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Balance Sheets (Unaudited)

(In US\$ thousands, except share and per share data)

|  | September 30,<br>2014 | June 30,<br>2014 |
|--|-----------------------|------------------|
| <b>Assets</b>  |                       |                  |
| Current assets:  |                       |                  |
| Cash and cash equivalents  | \$ 881,694            | \$ 905,730       |
| Accounts receivable, net of allowance for doubtful accounts of \$10,848 and \$10,971 at September 30, 2014 and June 30, 2014, respectively | 328,591               | 359,593          |
| Inventories (note 3)   | 197,226               | 165,418          |
| Deferred income taxes  | 36,270                | 31,908           |
| Income taxes receivable  | 2,577                 | 14,853           |
| Prepaid expenses and other current assets  | 88,392                | 78,707           |
| Total current assets   | 1,534,750             | 1,556,209        |
| Non-current assets:  |                       |                  |
| Property, plant and equipment, net (note 4)  | 419,786               | 434,277          |
| Goodwill and other intangible assets, net (note 6)   | 323,746               | 334,510          |
| Deferred income taxes  | 13,538                | 18,755           |
| Other assets   | 17,633                | 17,211           |
| Total non-current assets   | 774,703               | 804,753          |
| Total assets   | \$ 2,309,453          | \$ 2,360,962     |
| <b>Liabilities and Stockholders' Equity</b>  |                       |                  |
| Current liabilities:   |                       |                  |
| Accounts payable   | 76,248                | 85,405           |
| Accrued expenses   | 124,235               | 130,656          |
| Deferred revenue   | 39,543                | 42,370           |
| Income taxes payable   | 13,619                | 10,392           |
| Deferred income taxes  | 651                   | 717              |
| Current portion of long-term debt (note 7)   | -                     | 18               |
| Total current liabilities  | 254,296               | 269,558          |
| Non-current liabilities:   |                       |                  |
| Deferred income taxes  | 10,002                | 10,716           |
| Deferred revenue   | 14,489                | 16,352           |
| Long-term debt (note 7)  | 375,701               | 300,770          |
| Income taxes payable   | 1,754                 | 5,318            |
| Total non-current liabilities  | 401,946               | 333,156          |
| Total liabilities  | 656,242               | 602,714          |

# Edgar Filing: RESMED INC - Form 10-Q

|  |              |              |
|--|--------------|--------------|
| Commitments and contingencies (note 12)  |              |              |
| Stockholders' equity: (note 10)  |              |              |
| Preferred stock, \$0.01 par value, 2,000,000 shares authorized; none issued  | -            | -            |
| Common stock, \$0.004 par value, 350,000,000 shares authorized; 177,030,185 issued and 139,752,203 outstanding at September 30, 2014 and 176,747,039 issued and 140,304,544 outstanding at June 30, 2014 | 559          | 561          |
| Additional paid-in capital   | 1,136,528    | 1,117,644    |
| Retained earnings  | 1,824,457    | 1,780,396    |
| Treasury stock, at cost, 37,277,982 shares at September 30, 2014, and 36,442,495 shares at June 30, 2014   | (1,334,782)  | (1,291,910)  |
| Accumulated other comprehensive income   | 26,449       | 151,557      |
| Total stockholders' equity   | 1,653,211    | 1,758,248    |
| Total liabilities and stockholders' equity   | \$ 2,309,453 | \$ 2,360,962 |

See the accompanying notes to the unaudited condensed consolidated financial statements.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Income (Unaudited)

(In US\$ thousands, except per share data)

|  | Three Months Ended<br>September 30, |            |
|--|-------------------------------------|------------|
|  | 2014                                | 2013       |
| Net revenue                                | \$ 380,399                          | \$ 357,662 |
| Cost of sales                              | 143,086                             | 129,680    |
| Gross profit                               | 237,313                             | 227,982    |
| Operating expenses:                        |                                     |            |
| Selling, general and administrative        | 110,520                             | 101,323    |
| Research and development                   | 30,024                              | 27,363     |
| Amortization of acquired intangible assets | 2,094                               | 2,412      |
| Total operating expenses                   | 142,638                             | 131,098    |
| Income from operations                     | 94,675                              | 96,884     |
| Other income, net:                         |                                     |            |
| Interest income, net                       | 5,584                               | 6,414      |
| Other, net                                 | 1,671                               | (1,228)    |
| Total other income, net                    | 7,255                               | 5,186      |
| Income before income taxes                 | 101,930                             | 102,070    |
| Income taxes                               | 18,670                              | 21,140     |
| Net income                                 | \$ 83,260                           | \$ 80,930  |
| Basic earnings per share                   | \$ 0.59                             | \$ 0.57    |
| Diluted earnings per share (note 2)        | \$ 0.58                             | \$ 0.56    |
| Dividend declared per share                | \$ 0.28                             | \$ 0.25    |
| Basic shares outstanding (000 s)           | 140,127                             | 142,005    |
| Diluted shares outstanding (000 s)         | 142,683                             | 145,456    |

See the accompanying notes to the unaudited condensed consolidated financial statements.

---

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(In US\$ thousands)

|  | Three Months Ended<br>September 30, |            |
|--|-------------------------------------|------------|
|  | 2014                                | 2013       |
| Net income   | \$ 83,260                           | \$ 80,930  |
| Other comprehensive income:                          |                                     |            |
| Foreign currency translation gain (loss) adjustments | (125,108)                           | 38,203     |
| Comprehensive income                                 | \$ (41,848)                         | \$ 119,133 |

See the accompanying notes to the unaudited condensed consolidated financial statements.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

## Condensed Consolidated Statements of Cash Flows (Unaudited)

(In US\$ thousands)

|  | Three Months Ended<br>September 30, |           |
|--|-------------------------------------|-----------|
|  | 2014                                | 2013      |
| <b>Cash flows from operating activities:</b>                                     |                                     |           |
| Net income   | \$ 83,260                           | \$ 80,930 |
| Adjustment to reconcile net income to net cash provided by operating activities: |                                     |           |
| Depreciation and amortization  | 18,582                              | 17,870    |
| Gain on divestment of business   | (709)                               | -         |
| Stock-based compensation costs   | 11,367                              | 10,816    |
| Foreign currency revaluation   | 451                                 | (1,653)   |
| Excess tax benefit from stock-based compensation arrangements                    | (2,575)                             | (2,241)   |
| Changes in operating assets and liabilities, net of effect of acquisitions:      |                                     |           |
| Accounts receivable, net   | 20,804                              | 40,268    |
| Inventories, net   | (37,897)                            | (26,847)  |
| Prepaid expenses, net deferred income taxes and other current assets             | (15,168)                            | (4,451)   |
| Accounts payable, accrued expenses and other liabilities                         | 8,421                               | (24,267)  |
| Net cash provided by operating activities  | 86,536                              | 90,425    |
| <b>Cash flows from investing activities:</b>                                     |                                     |           |
| Purchases of property, plant and equipment                                       | (20,681)                            | (16,752)  |
| Patent registration costs  | (2,366)                             | (1,679)   |
| Business acquisitions, net of cash acquired                                      | (7,318)                             | -         |
| Investments in cost-method investments   | (500)                               | (675)     |
| Proceeds from divestiture of business  | 468                                 | -         |
| Payments on maturity of foreign currency contracts                               | (11,206)                            | (2,486)   |
| Net cash used in investing activities  | (41,603)                            | (21,592)  |
| <b>Cash flows from financing activities:</b>                                     |                                     |           |
| Proceeds from issuance of common stock, net                                      | 4,930                               | 6,470     |
| Excess tax benefit from stock-based compensation arrangements                    | 2,575                               | 2,241     |
| Purchases of treasury stock  | (46,803)                            | (22,822)  |
| Payment of business combination contingent consideration                         | (458)                               | (442)     |
| Proceeds from borrowings, net of borrowing costs                                 | 75,000                              | 60,000    |
| Repayment of borrowings  | (10)                                | (9)       |
| Dividend paid  | (39,199)                            | (35,478)  |
| Net cash used in financing activities  | (3,965)                             | 9,960     |
| Effect of exchange rate changes on cash  | (65,004)                            | 21,733    |
| Net increase in cash and cash equivalents  | (24,036)                            | 100,526   |
| Cash and cash equivalents at beginning of period                                 | 905,730                             | 876,048   |

# Edgar Filing: RESMED INC - Form 10-Q

|  |            |            |
|--|------------|------------|
| Cash and cash equivalents at end of period | \$ 881,694 | \$ 976,574 |
|--|------------|------------|

## Supplemental disclosure of cash flow information:

|                                   |           |           |
|-----------------------------------|-----------|-----------|
| Income taxes paid, net of refunds | \$ 14,373 | \$ 39,612 |
| Interest paid                     | \$ 1,233  | \$ 1,599  |

|   |          |      |
|---|----------|------|
| Fair value of assets acquired, excluding cash | \$ 7,342 | \$ - |
| Liabilities assumed                           | (3,168)  | -    |
| Goodwill on acquisition                       | 6,454    | -    |
| Deferred payments                             | (2,405)  | -    |
| Fair value of contingent consideration        | (905)    | -    |

|  |          |      |
|--|----------|------|
| Total purchase price, excluding contingent consideration | \$ 7,318 | \$ - |
|--|----------|------|

See the accompanying notes to the unaudited condensed consolidated financial statements.

## **Table of Contents**

### **PART I FINANCIAL INFORMATION**

Item 1

#### **RESMED INC. AND SUBSIDIARIES**

#### **Notes to the Condensed Consolidated Financial Statements**

**(Unaudited)**

##### **(1) Summary of Significant Accounting Policies**

###### **Organization and Basis of Presentation**

ResMed Inc. (referred to herein as we, us, our or the Company) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2015.

The condensed consolidated financial statements for the three months ended September 30, 2014 and 2013 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2014.

###### **New Accounting Pronouncements**

In May, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2018. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

##### **(2) Earnings Per Share**

Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.

The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 154,551 and 209,856 for the three months ended September 30, 2014 and 2013, respectively, as the effect of exercising these options would have been anti-dilutive.

Basic and diluted earnings per share for the three months ended September 30, 2014 and 2013 are calculated as follows (in thousands except per share data):

# Edgar Filing: RESMED INC - Form 10-Q

|  | Three Months Ended<br>September 30, |           |
|--|-------------------------------------|-----------|
|  | 2014                                | 2013      |
| Numerator:   |                                     |           |
| Net Income, used in calculating diluted earnings per share | \$ 83,260                           | \$ 80,930 |
| Denominator:   |                                     |           |
| Basic weighted-average common shares outstanding           | 140,127                             | 142,005   |
| Effect of dilutive securities:                             |                                     |           |
| Stock options and restricted stock units                   | 2,556                               | 3,451     |
| Diluted weighted average shares                            | 142,683                             | 145,456   |
| Basic earnings per share                                   | \$ 0.59                             | \$ 0.57   |
| Diluted earnings per share                                 | \$ 0.58                             | \$ 0.56   |

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)****(3) Inventories**

Inventories were comprised of the following at September 30, 2014 and June 30, 2014 (in thousands):

|                   | September 30, 2014 | June 30, 2014 |
|-------------------|--------------------|---------------|
| Raw materials     | \$ 58,024          | \$ 53,680     |
| Work in progress  | 3,761              | 3,358         |
| Finished goods    | 135,441            | 108,380       |
| Total inventories | \$ 197,226         | \$ 165,418    |

**(4) Property, Plant and Equipment**

Property, plant and equipment were comprised of the following as of September 30, 2014 and June 30, 2014 (in thousands):

|  | September 30, 2014 | June 30, 2014 |
|--|--------------------|---------------|
| Machinery and equipment                      | \$ 196,401         | \$ 200,929    |
| Computer equipment                           | 135,868            | 133,157       |
| Furniture and fixtures                       | 41,168             | 42,631        |
| Vehicles                                     | 3,583              | 4,757         |
| Clinical, demonstration and rental equipment | 93,503             | 101,453       |
| Leasehold improvements                       | 29,032             | 30,361        |
| Land   | 59,494             | 62,468        |
| Buildings                                    | 254,511            | 266,771       |
|  | 813,560            | 842,527       |
| Accumulated depreciation and amortization    | (393,774)          | (408,250)     |
| Property, plant and equipment, net           | \$ 419,786         | \$ 434,277    |

**(5) Cost-Method Investments**

The aggregate carrying amount of our cost-method investments at September 30, 2014 and June 30, 2014, was \$15.4 million and \$14.9 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.

We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows. During the three months ended September 30, 2014 and 2013, we recognized \$Nil and \$Nil, respectively, of impairment losses related to our cost-method investments. We have determined that the fair value of our investments exceed their carrying values.

## Edgar Filing: RESMED INC - Form 10-Q

The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2014 and 2013 (in thousands):

|  | Three Months Ended September 30, |          |
|--|----------------------------------|----------|
|  | 2014                             | 2013     |
| Balance at the beginning of the period | \$ 14,850                        | \$ 4,000 |
| Investments                            | 500                              | 675      |
| Balance at the end of the period       | \$ 15,350                        | \$ 4,675 |

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)****(6) Goodwill and Other Intangible Assets, net****Goodwill**

Changes in the carrying amount of goodwill for the three months ended September 30, 2014, and 2013 were as follows (in thousands):

|  | Three Months Ended September 30, |            |
|--|----------------------------------|------------|
|  | 2014                             | 2013       |
| Balance at the beginning of the period   | \$ 289,312                       | \$ 274,829 |
| Business acquisition                     | 6,454                            | -          |
| Foreign currency translation adjustments | (18,502)                         | 8,616      |
| Balance at the end of the period         | \$ 277,264                       | \$ 283,445 |

**Other Intangible Assets**

Other intangible assets are comprised of the following as of September 30, 2014, and June 30, 2014 (in thousands):

|  | September 30, 2014 | June 30, 2014 |
|--|--------------------|---------------|
| Developed/core product technology      | \$ 70,677          | \$ 76,015     |
| Accumulated amortization               | (51,642)           | (54,073)      |
| Developed/core product technology, net | 19,035             | 21,942        |
| Trade names                            | 2,803              | 2,784         |
| Accumulated amortization               | (2,508)            | (2,697)       |
| Trade names, net                       | 295                | 87            |
| Non-compete agreements                 | 1,982              | 2,135         |
| Accumulated amortization               | (1,715)            | (1,768)       |
| Non compete agreements, net            | 267                | 367           |
| Customer relationships                 | 28,368             | 24,593        |
| Accumulated amortization               | (19,834)           | (20,877)      |
| Customer relationships, net            | 8,534              | 3,716         |
| Patents                                | 67,872             | 70,734        |
| Accumulated amortization               | (49,521)           | (51,648)      |
| Patents, net                           | 18,351             | 19,086        |
| Total other intangibles, net           | \$ 46,482          | \$ 45,198     |

Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology. We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)****(7) Long-Term Debt**

Long-term debt at September 30, 2014 and June 30, 2014 consists of the following (in thousands):

|                            | September 30, 2014 | June 30, 2014 |
|----------------------------|--------------------|---------------|
| Current long-term debt     | \$ -               | \$ 18         |
| Non-current long-term debt | 375,701            | 300,770       |
| Total long-term debt       | \$ 375,701         | \$ 300,788    |

**Credit Facility**

On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries.

The credit agreement provides a \$700 million senior unsecured five-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional \$300 million. The credit facility also includes a \$25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2014, the interest rate that was being charged on the outstanding principal amount was 1.2%. An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility.

When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previous revolving credit facility with Union Bank, N.A. and other lenders. On that repayment, the previous credit agreement, dated as of February 10, 2011, between us and lenders (including Union Bank, N.A., as administrative agent, swing line lender and L/C Issuer, HSBC Bank USA, National Association, as syndication agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank), was terminated and the commitments under the previous credit agreement were also terminated.

Our obligations under the current credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC.

At September 30, 2014, there was \$375.0 million outstanding under the credit agreement.

**(8) Product Warranties**

## Edgar Filing: RESMED INC - Form 10-Q

Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the three months ended September 30, 2014 and 2013 are as follows (in thousands):

|  | Three Months Ended September 30, |           |
|--|----------------------------------|-----------|
|  | 2014                             | 2013      |
| Balance at the beginning of the period   | \$ 11,798                        | \$ 16,011 |
| Warranty accruals for the period         | 3,376                            | 2,796     |
| Warranty costs incurred for the period   | (1,567)                          | (2,270)   |
| Foreign currency translation adjustments | (714)                            | 368       |
| Balance at the end of the period         | \$ 12,893                        | \$ 16,905 |

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)****(9) Stock-Based Employee Compensation**

We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the ESPP) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.

We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:

|  | Three Months Ended September 30, |          |
|--|----------------------------------|----------|
|  | 2014                             | 2013     |
| Stock options:                           |                                  |          |
| Weighted average grant date fair value   | \$ -                             | \$ -     |
| Weighted average risk-free interest rate | -                                | -        |
| Expected option life in years            | -                                | -        |
| Dividend yield                           | -                                | -        |
| Expected volatility                      | -                                | -        |
| ESPP purchase rights:                    |                                  |          |
| Weighted average risk-free interest rate | 0.1%                             | 0.1%     |
| Expected option life in years            | 6 months                         | 6 months |
| Dividend yield                           | 2.00%                            | 1.44%    |
| Expected volatility                      | 24%                              | 24%      |

**(10) Stockholders' Equity**

**Common Stock.** During the three months ended September 30, 2014 and 2013 we repurchased 0.8 million and 0.4 million shares at a cost of \$42.9 million and \$21.1 million, respectively. Since the inception of our share repurchase programs and through September 30, 2014, we have repurchased a total of 37.3 million shares at a cost of \$1.3 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At September 30, 2014, 17.4 million additional shares can be repurchased under the approved share repurchase program.

**Preferred Stock.** In April 1997, the board of directors designated 2,000,000 shares of our \$0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2014 and June 30, 2014.

**Stock Options and Restricted Stock Units.** We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with ResMed Inc. 2009 Incentive Award Plan (the 2009 Plan). These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.

## Edgar Filing: RESMED INC - Form 10-Q

The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2014 is 16.2 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any full-value award, which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant's initial year of hiring, when up to 4.5 million shares of our common stock may be granted).

At September 30, 2014, there were \$62.1 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.1 years. The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2014 was \$225.0 million and \$93.9 million, respectively. The aggregate intrinsic value of the options exercised during the three months ended September 30, 2014 and 2013, was \$9.7 million and \$11.5 million, respectively.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)**

The following table summarizes option activity during the three months ended September 30, 2014:

|   |           | Weighted Average<br>Exercise Price | Weighted Average Remaining<br>Contractual Term<br>in Years |
|---|-----------|------------------------------------|--|
| Outstanding at beginning of period      | 4,687,220 | \$ 24.45                           | 2.6  |
| Granted                                 | -         | -                                  |  |
| Exercised                               | (297,969) | 18.56                              |  |
| Forfeited                               | (13,823)  | 34.00                              |  |
| Outstanding at end of period            | 4,375,428 | \$ 24.82                           | 2.4  |
| Exercise price range of granted options | -         |                                    |  |
| Options exercisable at end of period    | 3,399,349 | \$ 21.66                           |  |

The following table summarizes the activity of restricted stock units during the three months ended September 30, 2014:

|                                    |           | Weighted Average Grant-<br>Date Fair Value | Weighted Average Remaining<br>Contractual Term<br>in Years |
|------------------------------------|-----------|--|--|
| Outstanding at beginning of period | 2,448,331 | \$ 38.58                                   | 1.3  |
| Granted                            | 1,500     | 47.08                                      |  |
| Vested                             | (33,149)  | 30.95                                      |  |
| Forfeited                          | (24,189)  | 36.86                                      |  |
| Outstanding at end of period       | 2,392,493 | \$ 38.70                                   | 1.1  |

**Employee Stock Purchase Plan (the ESPP).** Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors' compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than \$25,000 in common stock during any calendar year. At September 30, 2014, the number of shares remaining available for future issuance under the ESPP is 1.8 million shares.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)****(11) Fair Value Measurements**

In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The hierarchies of inputs are as follows:

Level 1: Input prices quoted in an active market for identical financial assets or liabilities;

Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.

The following table summarizes our financial assets and liabilities, as at September 30, 2014 and June 30, 2014, using the valuation input hierarchy (in thousands):

|   | Level 1 | Level 2    | Level 3  | Total      |
|---|---------|------------|----------|------------|
| Balances at September 30, 2014                |         |            |          |            |
| Foreign currency hedging instruments, net     | \$ -    | \$ (2,048) | \$ -     | \$ (2,048) |
| Business acquisition contingent consideration | \$ -    | \$ -       | \$ (875) | \$ (875)   |
| Balances at June 30, 2014                     |         |            |          |            |
| Foreign currency hedging instruments, net     | \$ -    | \$ (2,270) | \$ -     | \$ (2,270) |
| Business acquisition contingent consideration | \$ -    | \$ -       | \$ (480) | \$ (480)   |

We determine the fair value of our financial assets and liabilities as follows:

**Foreign currency hedging instruments** These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.

**Contingent consideration** These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.

The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2014 (in thousands):

Three Months Ended September 30, 2014

## Edgar Filing: RESMED INC - Form 10-Q

|   |    |       |
|---|----|-------|
| Balance at the beginning of the period                  | \$ | (480) |
| Acquisition date fair value of contingent consideration |    | (905) |
| Changes in fair value included in operating income      |    | 132   |
| Payments  |    | 458   |
| Foreign currency translation adjustments                |    | (80)  |
| Balance at the end of the period                        | \$ | (875) |

We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2014 or June 30, 2014.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES****Notes to the Condensed Consolidated Financial Statements****(Unaudited)****(12) Legal Actions and Contingencies****Litigation**

In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.

**Contingent Obligations Under Recourse Provisions**

We use independent leasing companies to provide financing to certain customers for the purchase of our products. In some cases, we are contingently liable in the event of a customer default, to the leasing companies, within certain limits, for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold with recourse during the three months ended September 30, 2014 and 2013, amounted to \$2.0 million and \$0.8 million, respectively. The maximum potential amount of contingent liability under these arrangements at September 30, 2014 and June 30, 2014 were \$5.2 million, and \$4.9 million, respectively. The recourse liability recognized by us at September 30, 2014 and June 30, 2014, in relation to these arrangements was \$0.5 million and \$0.5 million, respectively.

**(13) Derivative Instruments and Hedging Activities**

We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.

We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.

We held foreign currency instruments with notional amounts totaling \$405.8 million and \$473.7 million at September 30, 2014 and June 30, 2014, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to September 30, 2017.

The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2014 and June 30, 2014 (in thousands):

|                                      | September 30, 2014 | June 30, 2014 | Balance Sheet Caption      |
|--------------------------------------|--------------------|---------------|----------------------------|
| Foreign currency hedging instruments | \$ 557             | \$ 456        | Other assets - current     |
| Foreign currency hedging instruments | 518                | 489           | Other assets - non current |
| Foreign currency hedging instruments | (3,123)            | (3,215)       | Accrued expenses           |

## Edgar Filing: RESMED INC - Form 10-Q

\$ (2,048)      \$ (2,270)

The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2014 and September 30, 2013, respectively (in thousands):

|   | Gain /(Loss) Recognized          |            | Income Statement Caption |
|---|----------------------------------|------------|--------------------------|
|   | Three Months Ended September 30, |            |                          |
|   | 2014                             | 2013       |                          |
| Foreign currency hedging instruments            | \$ (11,054)                      | \$ (3,156) | Other, net               |
| Other foreign-currency-denominated transactions | 12,148                           | 1,741      | Other, net               |
|   | \$ 1,094                         | \$ (1,415) |                          |

We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 1

**RESMED INC. AND SUBSIDIARIES**

**Notes to the Condensed Consolidated Financial Statements**

**(Unaudited)**

**(14) Business Combinations**

During the three months ended September 30, 2014 we acquired two, Australian-based distributors of equipment and services for the treatment of sleep-disordered breathing and respiratory disorders. These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from their respective acquisition dates. The acquisitions are not considered a material business combination and accordingly pro forma information is not provided. The acquisitions were funded through cash on-hand and we have not incurred any material acquisition related costs.

We have completed the preliminary purchase price allocation for the above acquisitions during the quarter. The cost of the acquisitions has been allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. As part of the preliminary purchase price allocation, we recognized an intangible asset relating to customer relationships of \$6.0 million, with an estimated useful life of 5 years, and goodwill of \$6.5 million. The goodwill recognized as part of these acquisitions, which is not deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 2

**RESMED INC. AND SUBSIDIARIES**

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Special Note Regarding Forward-Looking Statements**

This report contains certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words believe, expect, anticipate, will continue, will, estimate, plan, future and expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding the development and approval of new products and product applications, market expansion, pending litigation and the development of new markets for our products, such as cardiovascular and stroke markets. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our annual report on Form 10-K for the fiscal year ended June 30, 2014 and elsewhere in this report.

In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, economic, market, legal or regulatory circumstances, changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities and various other factors. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.

Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our annual report on Form 10-K, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.

## **Table of Contents**

### **PART I FINANCIAL INFORMATION**

Item 2

#### **RESMED INC. AND SUBSIDIARIES**

#### **Management's Discussion and Analysis of Financial Condition and Results of Operations**

##### **Overview**

The following is an overview of our results of operations for the three months ended September 30, 2014. Management's discussion and analysis of financial condition and results of operations is intended to help the reader understand the results of operations and financial condition of ResMed Inc. Management's discussion and analysis is provided as a supplement to, and should be read in conjunction with, the selected financial data and condensed consolidated financial statements and notes, included in this report.

We are a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing ( SDB ) and other respiratory disorders. During the three months ended September 30, 2014, we continued our efforts to build awareness of the consequences of untreated SDB, and to grow our business in this market. In our efforts, we have attempted to raise awareness through market and clinical initiatives highlighting the relationship between SDB/obstructive sleep apnea and co-morbidities, such as cardiac disease, diabetes, hypertension and obesity, as well as the dangers of sleep apnea in regard to occupational health and safety, especially in the transport industry.

We are committed to ongoing investment in research and development and product enhancements. During the three months ended September 30, 2014, we invested \$30.0 million on research and development activities. Since the development of continuous positive airway pressure ( CPAP ) therapy, we have developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Our new product release schedule remains active across both our mask and flow generator categories. We are taking steps to increase awareness of the health dangers of SDB by sponsoring educational programs targeted at the primary care physician community. We believe these efforts should further increase awareness of both doctors and patients about the relationship between SDB, obstructive sleep apnea and co-morbidities such as cardiac disease, diabetes, hypertension and obesity. We also believe these efforts should help inform the community of the dangers of sleep apnea in occupational health and safety, especially in the transport industry.

During the quarter, we launched innovative products for our sleep-disordered breathing and respiratory care markets. We have also recently launched two initiatives as part of our efforts to increase community awareness: an education and product-focused campaign called "Better Sleep for Women" ; and the recent launch of a new product "S+" by ResMed , the first non-contact sleep wellness tracking device for individuals.

During the three months ended September 30, 2014, our net revenue increased by 6% when compared to the three months ended September 30, 2013. Gross margin was 62.4% for the three months ended September 30, 2014 compared to 63.7% for the three months ended September 30, 2013. Diluted earnings per share for the three months ended September 30, 2014 increased to \$0.58 per share, up from \$0.56 per share in the three months ended September 30, 2013.

At September 30, 2014, our cash and cash equivalents totaled \$881.7 million, our total assets were \$2.3 billion and our stockholders' equity was \$1.7 billion.

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a "constant currency basis" , which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

**Table of Contents****PART I FINANCIAL INFORMATION**

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations****Net Revenue**

Net revenue increased for the three months ended September 30, 2014 to \$380.4 million compared to \$357.7 million for the three months ended September 30, 2013, an increase of \$22.7 million or 6% (also a 6% increase on a constant currency basis). The increase in net revenue is primarily attributable to an increase in unit sales of our flow generators, masks and accessories, partially offset by a decline in average selling prices. Movements in international currencies against the U.S. dollar favorably impacted revenues by approximately \$0.4 million for the three months ended September 30, 2014.

Net revenue in North and Latin America for the three months ended September 30, 2014 was \$207.2 million, compared to \$201.5 million for the three months ended September 30, 2013, an increase of \$5.7 million, or 3%. The increase net revenue is primarily attributable to an increase in unit sales of our flow generators, masks and accessories, offset by a decline in average selling prices. Net revenue in markets outside North and Latin America, for the three months ended September 30, 2014, increased to \$173.2 million compared to \$156.2 million for the three months ended September 30, 2013, an increase of 11% (also an 11% increase in constant currency terms).

Net revenue from the sales of flow generators, including humidifiers, for the three months ended September 30, 2014 totaled \$214.3 million, an increase of 12% compared to the three months ended September 30, 2013 of \$191.8 million, including an increase of 8% in North and Latin America and an increase of 15% elsewhere. Net revenue from the sales of masks and other accessories for the three months ended September 30, 2014 totaled \$166.1 million, compared to the three months ended September 30, 2013 of \$165.9 million, reflecting a decrease of 1% in North and Latin America and an increase of 2% elsewhere.

The following table summarizes the percentage movements in our net revenue for the three months ended September 30, 2014 compared to the three months ended September 30, 2013:

|                             | North and<br>Latin America | International | Total | International<br>(Constant<br>Currency)<br>* | Total<br>(Constant<br>Currency)* |
|-----------------------------|----------------------------|---------------|-------|--|----------------------------------|
| Flow generators             | 8%                         | 15%           | 12%   | 15%  | 12%                              |
| Masks and other accessories | -1%                        | 2%            | 0%    | 2%   | 0%                               |
| Total                       | 3%                         | 11%           | 6%    | 11%  | 6%                               |

\* Constant currency numbers exclude the impact of movements in international currencies.

**Gross Profit**

Gross profit increased for the three months ended September 30, 2014 to \$237.3 million from \$228.0 million for the three months ended September 30, 2013, an increase of \$9.3 million or 4%. Gross profit as a percentage of net revenue for the three months ended September 30, 2014 decreased to 62.4% from 63.7% for the three months ended September 30, 2013.

The decline in gross margins was primarily due to declines in our average selling prices, and unfavorable product mix as sales of our lower margin products represented a higher proportion of our sales, partially offset by manufacturing and supply chain improvements.

**Selling, General and Administrative Expenses**

## Edgar Filing: RESMED INC - Form 10-Q

Selling, general and administrative expenses increased for the three months ended September 30, 2014 to \$110.5 million from \$101.3 million for the three months ended September 30, 2013, an increase of \$9.2 million or 9% (also a 9% increase in constant currency terms). Selling, general and administrative expenses, as a percentage of net revenue, were 29.1% for the three months ended September 30, 2014, compared to 28.3% for the three months ended September 30, 2013.

The increase in selling, general and administrative expenses was primarily due to additional personnel to support our commercial activities, higher marketing expenditure associated with our recent product releases and an increase in our variable employee compensation costs.

## **Table of Contents**

### **PART I FINANCIAL INFORMATION**

Item 2

#### **RESMED INC. AND SUBSIDIARIES**

#### **Management's Discussion and Analysis of Financial Condition and Results of Operations**

##### **Research and Development Expenses**

Research and development expenses increased for the three months ended September 30, 2014 to \$30.0 million from \$27.4 million for the three months ended September 30, 2013, an increase of \$2.7 million, or 10% (a 9% increase in constant currency terms). Research and development expenses, as a percentage of net revenue, were 7.9% for the three months ended September 30, 2014, compared to 7.7% for the three months ended September 30, 2013.

The increase in research and development expenses was primarily due to an increase in expenses associated with healthcare informatics product development activities and clinical trials in the area of heart failure.

##### **Amortization of Acquired Intangible Assets**

Amortization of acquired intangible assets for the three months ended September 30, 2014 totaled \$2.1 million, compared to \$2.4 million for the three months ended September 30, 2013.

##### **Total Other Income, Net**

Total other income, net for the three months ended September 30, 2014 was \$7.3 million, an increase of \$2.1 million compared with \$5.2 million for the three months ended September 30, 2013. The increase in total other income, net, was due primarily to gains on foreign currency transactions and the gain on sale of a distribution business, partially offset by lower interest income resulting from lower interest rates on cash balances held.

##### **Income Taxes**

Our effective income tax rate of approximately 18.3% for the three months ended September 30, 2014 was lower than our effective income tax rate of approximately 20.7% for the three months ended September 30, 2013. During the three months ended September 30, 2014, there was a final resolution of a German tax audit relating to the 1997 and 1998 fiscal years. As a result, we recorded a net tax benefit of \$3.2 million. Excluding the impact of this one-time tax benefit, our effective tax rate for the three months ended September 30, 2014 would have been 21.5%. Our effective income tax rate is affected by the geographic mix of our taxable income, including the lower taxes associated with our Singapore and Malaysia manufacturing operations. Our Singapore and Malaysia operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2020. As of September 30, 2014, we have not provided for U.S. income taxes for the undistributed earnings of our foreign subsidiaries. We intend these earnings to be permanently reinvested outside the United States.

##### **Net Income and Earnings per Share**

As a result of the factors above, our net income for the three months ended September 30, 2014 was \$83.3 million compared to net income of \$80.9 million for the three months ended September 30, 2013, an increase of 3% over the three months ended September 30, 2013.

As a result of the increase in our net income and lower share count due to our stock repurchases, our diluted earnings per share for the three months ended September 30, 2014 were \$0.58 compared to \$0.56 for the three months ended September 30, 2013, an increase of 4%.

##### **Liquidity and Capital Resources**

As of September 30, 2014 and June 30, 2014, we had cash and cash equivalents of \$881.7 million and \$905.7 million, respectively. Working capital was \$1.3 billion and \$1.3 billion at September 30, 2014 and June 30, 2014, respectively.

## Edgar Filing: RESMED INC - Form 10-Q

As of September 30, 2014 and June 30, 2014, our cash and cash equivalent balances held within the United States amounted to \$37.8 million and \$29.0 million, respectively. Our remaining cash and cash equivalent balances at September 30, 2014 and June 30, 2014, of \$843.9 million and \$876.7 million, respectively, were held by our non-U.S. subsidiaries and would be subject to tax if repatriated. If these funds were needed for our operations in the United States, we would be required to accrue and pay United States taxes to repatriate these funds. However, we intend to permanently reinvest these funds outside of the United States and our current plans do not demonstrate a need to repatriate them to fund our United States operations. Our cash and cash equivalent balances are held at highly rated financial institutions.

Inventories at September 30, 2014 were \$197.2 million, an increase of \$21.9 million or 12% from the September 30, 2013 balance of \$175.4 million. The increase in inventories was mainly associated with our new product introductions.

**Table of Contents****PART I FINANCIAL INFORMATION**

Item 2

**RESMED INC. AND SUBSIDIARIES****Management's Discussion and Analysis of Financial Condition and Results of Operations**

Accounts receivable at September 30, 2014 were \$328.6 million, an increase of \$46.2 million or 16% over the September 30, 2013 accounts receivable balance of \$282.4 million. Accounts receivable days outstanding of 78 days at September 30, 2014 was 9 days higher than the 69 days at September 30, 2013. The increase in our accounts receivable balance and days sales is reflecting the impact of longer payment terms given to our customers in our domestic market. Our allowance for doubtful accounts as a percentage of total accounts receivable at September 30, 2014 was 3.2%, compared to 3.0% at June 30, 2014.

During the three months ended September 30, 2014, we generated cash of \$86.5 million from operations compared to 90.4 million for the three months ended September 30, 2013. Movements in foreign currency exchange rates during the three months ended September 30, 2014 had the effect of decreasing our cash and cash equivalents by \$65.0 million, as reported in U.S. dollars. During the three months ended September 30, 2014 and 2013, we repurchased 0.8 million and 0.4 million shares at a cost of \$42.9 million and \$21.1 million, respectively. During the three months ended September 30, 2014 and 2013, we also paid dividends totaling \$39.2 million and \$35.5 million, respectively.

Capital expenditures for the three months ended September 30, 2014 and 2013 amounted to \$20.7 million and \$16.8 million, respectively. The capital expenditures for the three months ended September 30, 2014 primarily reflected investment in production tooling, equipment and machinery, computer hardware and software, and rental and loan equipment. At September 30, 2014, our balance sheet reflects net property, plant and equipment of \$419.8 million compared to \$434.3 million at June 30, 2014. At September 30, 2014, no capital lease obligations exist. Details of contractual obligations at September 30, 2014 are as follows:

| In \$000 s                 | Total      | Payments Due by September |           |           |           |            |            |
|----------------------------|------------|---------------------------|-----------|-----------|-----------|------------|------------|
|                            |            | 2015                      | 2016      | 2017      | 2018      | 2019       | Thereafter |
| Long Term Debt             | \$ 375,701 | \$ -                      | \$ -      | \$ -      | \$ -      | \$ 375,000 | \$ 701     |
| Interest on Long Term Debt | 19,820     | 4,834                     | 4,834     | 4,834     | 4,834     | 434        | 50         |
| Operating Leases           | 60,695     | 17,173                    | 12,452    | 8,525     | 5,447     | 3,305      | 13,793     |
| Purchase Obligations       | 148,960    | 148,848                   | 112       | -         | -         | -          | -          |
| Total                      | \$ 605,176 | \$ 170,855                | \$ 17,398 | \$ 13,359 | \$ 10,281 | \$ 378,739 | \$ 14,544  |

Details of other commercial commitments as at September 30, 2014 are as follows:

| In \$000 s  | Total     | 2015     | Amount of Commitment Expiration Per Period |          |      |      |            |
|-------------|-----------|----------|--|----------|------|------|------------|
|             |           |          | 2016                                       | 2017     | 2018 | 2019 | Thereafter |
| Guarantees* | \$ 13,530 | \$ 1,970 | \$ 4                                       | \$ 1,680 | \$ 1 | \$ 1 | \$ 9,874   |
| Total       | \$ 13,530 | \$ 1,970 | \$ 4                                       | \$ 1,680 | \$ 1 | \$ 1 | \$ 9,874   |

\* The above guarantees mainly relate to requirements under contractual obligations with insurance companies transacting with our German subsidiaries and guarantees provided under our facility leasing obligations.

**Credit Facility**

On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries.

## Edgar Filing: RESMED INC - Form 10-Q

The credit agreement provides a \$700 million senior unsecured five-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional \$300 million. The credit facility also includes a \$25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2014, the interest rate that was being charged on the outstanding principal amount was 1.2%. An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility.

When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previous revolving credit facility with Union Bank, N.A and other lenders. On that repayment, the previous credit agreement, dated as of February 10, 2011, between us and lenders (including Union Bank, N.A., as administrative agent, swing line lender and L/C Issuer, HSBC Bank USA, National Association, as syndication agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank), was terminated and the commitments under that previous credit agreement were also terminated.

## **Table of Contents**

### **PART I FINANCIAL INFORMATION**

Item 2

#### **RESMED INC. AND SUBSIDIARIES**

#### **Management's Discussion and Analysis of Financial Condition and Results of Operations**

Our obligations under the current credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC.

At September 30, 2014, we were in compliance with our debt covenants and there was \$375.0 million outstanding under the credit agreement.

We expect to satisfy all of our liquidity requirements through a combination of cash on hand, cash generated from operations and debt facilities.

#### **Common Stock**

During the three months ended September 30, 2014, we repurchased 0.8 million shares at a cost of \$42.9 million. At September 30, 2014, we have repurchased a total of 37.3 million shares at a cost of \$1.3 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At September 30, 2014, 17.4 million additional shares can be repurchased under the current share repurchase program.

#### **Critical Accounting Principles and Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.

We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

For a full discussion of our critical accounting policies, see our Annual Report on Form 10-K for the year ended June 30, 2014.

#### **Recently Issued Accounting Pronouncements**

See note 1 to the condensed consolidated financial statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.

#### **Off-Balance Sheet Arrangements**

As of September 30, 2014, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Quantitative and Qualitative Disclosures About Market Risk****Foreign Currency Market Risk**

Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollar. We have significant foreign currency exposure through our Australian and Singapore manufacturing activities and our international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures predominantly denominated in euros, Australian dollars and Singapore dollars. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not enter into financial instruments for trading or speculative purposes. The foreign currency derivatives portfolio is recorded in the condensed consolidated balance sheets at fair value and included in other assets or other liabilities. All movements in the fair value of the foreign currency derivatives are recorded within other income, net, on our condensed consolidated statements of income.

The table below provides information (in U.S. dollars) on our foreign-currency-denominated balances by legal entity functional currency as of September 30, 2014 (in thousands):

|                         | Australian<br>Dollar<br>(AUD) | U.S.<br>Dollar<br>(USD) | Euro<br>(EUR) | Singapore<br>Dollar<br>(SGD) | Canadian<br>Dollar<br>(CAD) | British<br>Pound<br>(GBP) | Malaysian<br>Ringgit<br>(MYR) |
|-------------------------|-------------------------------|-------------------------|---------------|------------------------------|-----------------------------|---------------------------|-------------------------------|
| <b>AUD Functional:</b>  |                               |                         |               |                              |                             |                           |                               |
| Assets                  | -                             | 207,994                 | 143,935       | -                            | -                           | -                         | 3,067                         |
| Liabilities             | -                             | (61,675)                | (42,873)      | (1,148)                      | (9,264)                     | (5,026)                   | -                             |
| Forward Contracts       | -                             | (155,000)               | (75,782)      | -                            | -                           | 6,484                     | -                             |
| Net Total               | -                             | (8,681)                 | 25,280        | (1,148)                      | (9,264)                     | 1,458                     | 3,067                         |
| <b>USD Functional:</b>  |                               |                         |               |                              |                             |                           |                               |
| Assets                  | -                             | -                       | -             | -                            | 13,096                      | -                         | -                             |
| Liability               | -                             | -                       | (157)         | -                            | (735)                       | -                         | -                             |
| Forward Contracts       | -                             | -                       | -             | -                            | -                           | -                         | -                             |
| Net Total               | -                             | -                       | (157)         | -                            | 12,361                      | -                         | -                             |
| <b>EURO Functional:</b> |                               |                         |               |                              |                             |                           |                               |
| Assets                  | 94                            | 477                     | -             | -                            | -                           | 3,523                     | -                             |
| Liability               | -                             | (1,383)                 | -             | -                            | (6)                         | (117)                     | -                             |
| Forward Contracts       | -                             | -                       | -             | -                            | -                           | (3,242)                   | -                             |
| Net Total               | 94                            | (906)                   | -             | -                            | (6)                         | 164                       | -                             |
| <b>GBP Functional:</b>  |                               |                         |               |                              |                             |                           |                               |
| Assets                  | -                             | 367                     | 43,396        | -                            | -                           | -                         | -                             |
| Liability               | -                             | (5)                     | (39,104)      | -                            | -                           | -                         | -                             |
| Forward Contracts       | -                             | -                       | -             | -                            | -                           | -                         | -                             |
| Net Total               | -                             | 362                     | 4,292         | -                            | -                           | -                         | -                             |
| <b>SGD Functional :</b> |                               |                         |               |                              |                             |                           |                               |
| Assets                  | 806                           | 122,014                 | 58,835        | -                            | -                           | -                         | -                             |
| Liability               | (1,842)                       | (78,629)                | (38,077)      | -                            | -                           | (7)                       | -                             |
| Forward Contracts       | -                             | (15,000)                | (18,945)      | -                            | -                           | -                         | -                             |
| Net Total               | (1,036)                       | 28,385                  | 1,813         | -                            | -                           | (7)                       | -                             |
| <b>SEK Functional :</b> |                               |                         |               |                              |                             |                           |                               |

# Edgar Filing: RESMED INC - Form 10-Q

|                   |      |         |       |     |   |   |   |
|-------------------|------|---------|-------|-----|---|---|---|
| Assets            | -    | -       | 3,301 | -   | - | - | - |
| Liability         | -    | -       | (272) | -   | - | - | - |
| Forward Contracts | -    | -       | -     | -   | - | - | - |
| Net Total         | -    | -       | 3,029 | -   | - | - | - |
| MYR Functional:   |      |         |       |     |   |   |   |
| Assets            | -    | 1,991   | 60    | -   | - | - | - |
| Liability         | (56) | (1,099) | (169) | (3) | - | - | - |
| Forward Contracts | -    | -       | -     | -   | - | - | - |
| Net Total         | (56) | 892     | (109) | (3) | - | - | - |

**Table of Contents**

## PART I FINANCIAL INFORMATION

Item 3

**RESMED INC. AND SUBSIDIARIES****Quantitative and Qualitative Disclosures About Market Risk**

The table below provides information about our foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options, collars and forward contracts held at September 30, 2014. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments, including the forward contracts used to hedge our foreign currency denominated assets and liabilities. These notional amounts generally are used to calculate payments to be exchanged under the contracts (in thousands, except exchange rates).

|                                |                     |                     |        |                      | Fair Value Assets /<br>(Liabilities) |               |
|--------------------------------|---------------------|---------------------|--------|----------------------|--------------------------------------|---------------|
| Foreign Exchange Contracts     | Year 1              | Year 2              | Year 3 | Total                | September 30, 2014                   | June 30, 2014 |
| <b>Receive AUD/Pay USD</b>     |                     |                     |        |                      |                                      |               |
| Contract amount                | 160,000             | -                   | -      | 160,000              | (766)                                | 328           |
| Ave. contractual exchange rate | AUD 1 = USD 0.8817  |                     |        | AUD 1 = USD 0.8817   |                                      |               |
| <b>Receive AUD/Pay Euro</b>    |                     |                     |        |                      |                                      |               |
| Contract amount                | 152,000             | 50,000              |        | 202,000              | (1,275)                              | (2,574)       |
| Ave. contractual exchange rate | AUD 1 = Euro 0.7397 | AUD 1 = Euro 0.7295 | -      | AUD 1 = Euro 0. 7371 |                                      |               |
| <b>Receive SGD/Pay Euro</b>    |                     |                     |        |                      |                                      |               |
| Contract amount                | 19,000              | -                   | -      | 19,000               | 52                                   | (90)          |
| Ave. contractual exchange rate | SGD 1 = Euro 0.6190 |                     |        | SGD 1 = Euro 0.6190  |                                      |               |
| <b>Receive SGD/Pay USD</b>     |                     |                     |        |                      |                                      |               |
| Contract amount                | 15,000              | -                   | -      | 15,000               | (12)                                 | 59            |
| Ave. contractual exchange rate | SGD 1 = USD 0.7846  |                     |        | SGD 1 = USD 0.7846   |                                      |               |
| <b>Receive GBP/Pay AUD</b>     |                     |                     |        |                      |                                      |               |
| Contract amount                | 6,000               | -                   | -      | 6,000                | (37)                                 | 18            |
| Ave. contractual exchange rate | AUD 1 = GBP 0.5338  |                     |        | AUD 1 = GBP 0.5338   |                                      |               |
| <b>Receive EUR/Pay GBP</b>     |                     |                     |        |                      |                                      |               |
| Contract amount                | 3,000               | -                   | -      | 3,000                | (10)                                 | (11)          |
| Ave. contractual exchange rate | EUR 1 = GBP 0.7815  |                     |        | EUR 1 = GBP 0.7815   |                                      |               |
| <b>Interest Rate Risk</b>      |                     |                     |        |                      |                                      |               |

We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At September 30, 2014, we held cash and cash equivalents of \$881.7 million, principally comprised of bank term deposits and at-call accounts, and they are invested at short-term fixed and variable interest rates. At September 30, 2014, we had total long-term debt, including the current portion of those obligations of \$375.7 million, of which \$375.0 million is subject to variable interest rates. A hypothetical 10% change in interest rates during the three months ended September 30, 2014, would not have had a material impact on pretax income. We have no interest rate hedging agreements.

**Table of Contents**

PART I FINANCIAL INFORMATION

Item 4

**RESMED INC. AND SUBSIDIARIES**

**Controls and Procedures**

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2014.

There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

**Table of Contents**

## PART II OTHER INFORMATION

Item 1-6

**RESMED INC. AND SUBSIDIARIES****Item 1 Legal Proceedings**

We have initiated several legal proceedings to enforce our intellectual property rights. Litigation is inherently uncertain. Accordingly, we cannot predict the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.

In 2013, we initiated actions in the U.S. and Germany against Taiwanese manufacturer APEX to stop the infringement of several ResMed patents. In September 2014, we entered into a settlement, resolving all our outstanding patent disputes with APEX, on confidential terms. After the settlement, at the request of the parties, the patent litigation we initiated was dismissed, and the US Patent & Trademark Office dismissed APEX's validity challenges to ResMed's patents. Patent validity challenges that were pending against ResMed in Germany, Japan and China were also dismissed, leaving only a proceeding in the European patent office still pending.

In 2013, we filed actions in the U.S. and Germany against Chinese manufacturer BMC Medical Co., Ltd to stop the infringement of several ResMed patents. The U.S. International Trade Commission initiated an investigation, and in August 2014, made an initial determination and recommendation that certain of BMC's humidifiers and masks infringed ResMed's patents and should be excluded from importation or sale in the US. The International Trade Commission has not made a final determination in this matter. In 2013, we obtained a preliminary injunction prohibiting BMC from marketing and selling certain products accused of patent infringement in Germany. It remains in effect until November 2014. Proceedings in Germany continue regarding other ResMed patents.

**Item 1A Risk Factors**

The discussion of our business and operations should be read together with the risk factors contained in our annual report on Form 10-K for the fiscal year ended June 30, 2014, which was filed with the SEC and describes the various risks and uncertainties to which we are or may become subject. At September 30, 2014, there have been no material changes to the risk factors set forth in our annual report on Form 10-K for the year ended June 30, 2014.

**Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**

Purchases of equity securities. The following table summarizes purchases by us of our common stock during the nine months ended September 30, 2014:

| Period                 | Total Number<br>of Shares<br>Purchased | Average Price<br>Paid per Share | Total Number of Shares<br>Purchased as Part<br>of<br>Publicly Announced<br>Programs <sup>(1)</sup> | Maximum Number of Shares<br>that May Yet Be<br>Purchased<br>Under the Program <sup>(1)</sup> |
|------------------------|--|---------------------------------|--|--|
| July 1 - 31, 2014      | 182,579                                | \$ 49.50                        | 36,625,074   | 18,090,939   |
| August 1 - 31, 2014    | 257,986                                | 51.65                           | 36,883,060   | 17,832,953   |
| September 1 - 30, 2014 | 394,922                                | 51.93                           | 37,277,982   | 17,438,031   |
| Total                  | 835,487                                | 51.31                           | 37,277,982   | 17,438,031   |

- (1) On February 21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. This program canceled and replaced our previous share repurchase program authorized on August 24, 2011, under which we

## Edgar Filing: RESMED INC - Form 10-Q

had repurchased 18.1 million shares. The 20 million shares the new program authorizes us to purchase are in addition to the shares we repurchased on or before February 21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program. Since the inception of the share buyback programs, we have repurchased 37.3 million shares at a total cost of \$1.3 billion.

### **Item 3**      **Defaults Upon Senior Securities**

None

### **Item 4**      **Mine Safety Disclosures**

None

### **Item 5**      **Other Information**

None

---

**Table of Contents**

PART II OTHER INFORMATION

Item 1-6

**RESMED INC. AND SUBSIDIARIES**

**Item 6 Exhibits**

Exhibits (numbered in accordance with Item 601 of Regulation S-K)

- 3.1 First Restated Certificate of Incorporation of ResMed Inc., as amended. (Incorporated by reference to Exhibit 3.1 to the Registrant's Report on Form 10-Q for the quarter ended September 30, 2013)
- 3.2 Fifth Amended and Restated Bylaws of ResMed Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K/A filed on September 17, 2012)
- 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101 The following financial statements from ResMed Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed on October 30, 2014, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows, (v) the Notes to the Condensed Consolidated Financial Statements.

**Table of Contents**

PART II OTHER INFORMATION

Signatures

**RESMED INC. AND SUBSIDIARIES**

**Signatures**

We have authorized the persons whose signatures appear below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

October 30, 2014

ResMed Inc.

**/s/ MICHAEL J. FARRELL**

Michael J. Farrell  
Chief executive officer  
(Principal Executive Officer)

**/s/ BRETT A. SANDERCOCK**

Brett A. Sandercock  
Chief financial officer  
(Principal Financial Officer)